PNA DEPENDENT GENE CHEMISTRY TO BOOST PLASMID EXPRESSION

Information

  • Research Project
  • 6174252
  • ApplicationId
    6174252
  • Core Project Number
    R44CA080598
  • Full Project Number
    5R44CA080598-03
  • Serial Number
    80598
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/1/1999 - 25 years ago
  • Project End Date
    6/30/2001 - 23 years ago
  • Program Officer Name
    FORRY-SCHAUDIES, SUZANNE L.
  • Budget Start Date
    7/1/2000 - 24 years ago
  • Budget End Date
    6/30/2001 - 23 years ago
  • Fiscal Year
    2000
  • Support Year
    3
  • Suffix
  • Award Notice Date
    7/6/2000 - 24 years ago

PNA DEPENDENT GENE CHEMISTRY TO BOOST PLASMID EXPRESSION

A straightforward and versatile approach to permanently introduce new physical and biological properties into DNA by irreversible chemical modification of plasmid would be a useful tool in the design and implementation of synthetic gene delivery systems for gene therapy applications. However, all of the currently available methods for chemically modifying plasmid damage the DNA and interfere with its transcriptional activity. The purpose of this grant is to provide proof of concept for a non- damaging approach to irreversibly modify DNA. The method takes advantage of the property of some peptide nucleic acids (PNA) to hybridize to duplex DNA in a very high affinity and sequence-specific manner. To demonstrate this gene chemistry approach a fluorescent PNA conjugate will be hybridized to a specific site cloned into a plasmid. The fluorescent signal from the PNA will be utilized to determine the stoichiometry, specificity, binding affinity and reversibility of the PNA bound to its target sequence. Transcriptional activity of an expression plasmid with and without PNA will be compared. The use of the fluorescent PNA in association with a plasmid encoding green fluorescent protein will be evaluated as a dual fluorescent system for simultaneous quantitative monitoring of plasmid DNA biodistribution and plasmid based gene expression. PROPOSED COMMERCIAL APPLICATION: The phase II grant proceeds will be used to design the next generation of pGeneGrip(TM) Vectors which will contain Nuclear Localization Peptides, Endosomal Lytic Peptides, Receptor Specific Ligands and Transcription Activators. The resources from the phase II grant application will be used to make the pGeneGrip(TM) Vectors available to research scientists performing DNA bioavailability studies in vitro and in vivo.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R44
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    430889
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:430889\
  • Funding Mechanism
  • Study Section
    ZMH1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    GENE THERAPY SYSTEMS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    92121
  • Organization District
    UNITED STATES